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Abstract
Background:  Array-based comparative genomic hybridization (CGH) is a commonly-used
approach to detect DNA copy number variation in whole genome-wide screens. Several statistical
methods have been proposed to define genomic segments with different copy numbers in cancer
tumors. However, most tumors are heterogeneous and show variation in DNA copy numbers
across tumor cells. The challenge is to reveal the copy number profiles of the subpopulations in a
tumor and to estimate the percentage of each subpopulation.
Results: We describe a relation between experimental data and exact DNA copy number and
develop a statistical method to reveal the heterogeneity of tumors containing a mixture of
different-stage cells. Furthermore, we validate the method on simulated data and apply the method
to 29 pairs of breast primary tumors and their matched lymph node metastases.
Conclusion: We demonstrate a new method for CGH array analysis that allows a tumor sample
to be classified according to its heterogeneity. The method gives an interpretable series of copy
number profiles, one for each major subpopulation in a tumor. The profiles facilitate identification
of copy number alterations in cancer development.
Background
Heterogeneity is an important characteristic of most can-
cers. It manifests itself in various different ways, for exam-
ple as heterogeneity in gene expression, protein
abundance and/or genomic DNA copy number [1-3]. In
this paper we focus exclusively on heterogeneity in
genomic DNA copy number. Genomic DNA copy number
variation in a tumor reflects concomitant or successive
development of various foci and indicates that malignant
transformation of cells is a dynamic evolutionary process.
Numerous studies have demonstrated that the develop-
ment of tumors involves accumulation of various genetic
alterations [4-8]. Comparative genomic hybridization
(CGH), matrix-based BAC/oligo array CGH, or oligonu-
cleotide-based arrays are techniques that frequently are
applied to elucidate intertumor heterogeneity across can-
cers, patients or stages; the genomic profile of a tumor is
presented at a fixed time point and averaged across differ-
ent cells in the tumor.
In contrast, intratumor heterogeneity is rarely reported [9].
Laser-capture micro-dissection is a powerful tool to select
few phenotypically homogeneous tumor cells, and thus a
way circumvent the problem of averaging across many
potentially inhomogeneous tumor cells. Methods for
whole genome amplification enable researchers to obtain
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sufficient DNA for CGH analysis even from few cells [10].
In this way the genomic profile of a small (homogeneous)
region in the tumor can be studied, whereas the heteroge-
neity of the tumor might be elucidated by investigating
several different regions across the tumor. Naturally, the
latter is time-consuming and labor intensive, and to our
knowledge, has not been reported.
With the above in mind, we have developed a statistical
method to study tumor heterogeneity. It takes CGH array
data from individual tumors as input; one tumor sample
is represented by one array and contains DNA from a
potentially heterogeneous cell population. Our method
estimates the number of dominant tumor subpopula-
tions, the percentages of the subpopulations in the sam-
ple, and the copy number profiles of the dominant
subpopulations. Also, the method estimates the percent-
age of normal cells. Normal cells are diploid (two copies
of all genomic DNA) and typically consist of nonmalig-
nant epithelium, fibroblast and/or penetrated lym-
phocytes. To validate the method we have simulated data
according to a model derived from real CGH data. Addi-
tionally, we have mixed some real tumor samples to
obtain samples with partially known profiles. Subse-
quently, we applied our method to 29 paired primary and
lymph node metastasis breast cancer samples.
Our method can be considered a classifier in the sense
that it assigns a number of subpopulations to a given
tumor sample. Alternatively the method might be consid-
ered as a model selection procedure over an extensive
number of models: We seek the model that explains the
data best, optimizing over the number of subpopulations
and the copy number profile for each subpopulation.
Results and discussion
Calibration experiment
A series of calibration experiments were conducted to test
the array CGH platform in our laboratory. The majority of
samples were from normal males and females (diploid
samples), but some samples were from patients with
genomic abnormalities, e.g. trisomies and monosomies.
Importantly, all these samples are assumed to be homoge-
neous, i.e. all cells in a sample have the same copy
number alteration(s). We fit a linear model to describe the
relationship between log-copy number and log-intensity;
as described in Methods (The copy number model). The
parameters of the linear model, y = αx + β, are estimated
to   = 0.6049, 95% CI: (0.5542,0.6556), and   = -
0.039, 95% CI (-0.085,0.0067), respectively. The
observed and fitted values show high correlation; Pear-
son's regression coefficient R2 is greater than 0.98. The
observed values and the regression line are shown [see
Additional file 1].
Heterogeneity in real tumors
We applied the procedure described in Methods (Classi-
fication of samples) to estimate the level of genomic het-
erogeneity in 29 pairs of primary tumor and lymph node
metastasis.
The method allows us to estimate the number of domi-
nant subpopulations, the copy number profile and the
percentage of cells in each subpopulation. Our method
assumes a model of sequential tumor evolution where
each subpopulation is evolved from the previous popula-
tion by introducing new aberrations, or by making aberra-
tions in the previous population more extreme, i.e. by
increasing copy numbers or decreasing copy numbers, see
Methods (Mixture modeling of tumor samples) for
details.
The results from the analysis of the primary tumor and
lymph node metastasis are shown in details [see Addi-
tional file 2] and summarized in Table 1. To estimate the
complexity of a tumor, we introduce the following meas-
ure called the Aberration Index (AI),
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Table 1: Subpopulation summary of the 29 pairs of primary and metastasis samples
# P1 P2 P3 AI1 AI2 AI3 Total Pure
T-2 15 25.3 (8.8) - - 1.13 (0.76) - - 0.25 (0.13) 1.13 (0.76)
T-3 13 33.4 (9.4) 14.2 (5.1) - 0.34 (0.13) 1.18 (0.26) - 0.28 (0.10) 0.59 (0.20)
T-4 1 23 (-) 34 (-) 8 (-) 0.25 (-) 0.53 (-) 1.40 (-) 0.35 (-) 0.54 (-)
M-2 16 24.8 (8.3) - - 1.07 (1.00) - - 0.21 (0.11) 1.07 (1.00)
M-3 10 32.5 (8.7) 15.1 (6.1) - 0.45 (0.23) 1.33 (0.41) - 0.33 (0.12) 0.71 (0.30)
M-4 3 16.7 (3.1) 31 (6) 8.7 (2.1) 0.18 (0.04) 0.48 (0.11) 1.33 (0.17) 0.29 (0.05) 0.52 (0.09)
The table summarizes the analysis done on the 29 pairs of samples [see Additional file 2]. Shown are mean values with standard deviation in 
parenthesis. T-i: Primary tumor with i subpopulations, M-i: Metastasis with i subpopulations, #: Number of samples, pk: Percentage of (abnormal) 
subpopulation k ≥ 1, AIk: Aberration Index for subpopulation k, Total: Weighted sum of AIk, ΣkpkAIk, Pure: AI•, normalized weighted sum of AIk, cf. 
equation (2).BMC Bioinformatics 2009, 10:12 http://www.biomedcentral.com/1471-2105/10/12
Page 3 of 11
(page number not for citation purposes)
where mi is the number of clones in segment i, Cik the copy
number of segment i in subpopulation k, and |x| denotes
the absolute value of x. Here we assume clones are uni-
formly spaced across the genome; if this is not the case the
contribution from each clone can be weighted by its dis-
tance to neighbor clones. The estimated subpopulations
are named P0, P1, P2, ..., and ordered according to
increasing AI. P0 consists of normal cells only and has AI0
= 0.
Tumors with only one abnormal subpopulation have
higher average AI than tumors with many abnormal sub-
populations; see Table 1. Also, the average complexity of
all abnormal subpopulations in a tumor,
("Pure" in Table 1) where pk denotes the percentage of
subpopulation k, is decreasing with the number of sub-
populations. This is re ecting that the percentage of the
most complex subpopulation is generally not very high,
whereas the percentage of the least complex is relatively
much higher.
We clustered all subpopulation profiles, rather than just
the overall profiles of the samples. The result, shown in
Figure 1, presents the similarity among all subpopulations
across the 29 tumor pairs. In 16 cases (out of 29) all pri-
mary and metastasis subpopulations cluster together
(shown in blue in the figure), i.e. the subpopulations of
the metastasis are more similar to the subpopulations of
the primary tumor than to subpopulations of other sam-
ples. The high similarity between the primary tumor and
the lymph node metastasis from the same patient indi-
cates that biological characteristics of the primary tumor
are maintained in the lymph node metastasis. In other
samples the primary tumor and the metastasis show much
less similarity, and even within a sample, the subpopula-
tions can be very dissimilar. The yellow cluster in Figure 1
consists mainly of subpopulations with low AI, i.e. few
genomic aberrations.
Table 2 shows the relationship between the estimated
number of subpopulations in the primary tumor and in
the corresponding metastasis. There is not a clear relation-
ship between the two numbers with only 14 pairs out of
29 showing the same subpopulation number. Of the 16
tumor pairs that clustered together in Figure 1 (see above
paragraph), 10 pairs have the same subpopulation
number while in 4 cases the metastasis shows a lower
number than the primary tumor.
The average percentage of the normal cell subpopulation
in a tumor is around 60%, which is higher than we
AI
pkAIk
p
k
•
>
=
− ∑ 1 0 0
, (2)
Cluster diagram of the 29 pairs of tumors Figure 1
Cluster diagram of the 29 pairs of tumors. The 29 pairs 
of primary and metastasis samples were divided into 89 sub-
populations using the method described in the paper. For 
two leaves with the same ID (e.g. T53), P1 refers to the 
abnormal subpopulation with the least aberration, P2 (if it 
exists) refers to the subpopulation with more aberrations 
than P1, and P3 (if it exists) the one with most aberrations. 
The percentage of each subpopulation is also included. The 
cluster diagram was generated using average linkage cluster-
ing based on the estimated copy numbers for all 3340 clones. 
Reducing the number of clones produces very similar results.BMC Bioinformatics 2009, 10:12 http://www.biomedcentral.com/1471-2105/10/12
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expected. According to the pathologists involved in
removing the tumors by surgery, the samples contain at
least 70% malignant cells. However, this percentage is
judged by eye and represents how big a fraction of the
tumor that appears to consist of normal cells. This is likely
to be an overestimate because malignant cells generally
are bigger than normal cells [11]. Also, some normal cells
are typically removed before the samples are subjected to
array analysis.
Finally, based on our results, we can make some predic-
tions about possible subpopulation developments in
paired tumor samples (Figure 2). For example, the P1 (P2)
subpopulations from the samples T51 and M51 cluster
together and they are likely immigrated from the primary
tumor to the lymph node as a whole. Whereas, for exam-
ple the subpopulations of M84 do not cluster together
with T84-P1, which might indicate that the metastasis has
arisen from the T84-P2 in the primary tumor.
Simulation results
We simulated samples based on the 29 pairs of real sam-
ples (in total 58 samples), as described in the Methods
(Simulation). For each real sample we fit copy number
profiles assuming 2, 3 or 4 subpopulations and use these
profiles as templates for simulation of artificial log-inten-
sities. For example, for a real sample with an estimated 2
subpopulations, we fit 2, 3 and 4 subpopulations and
simulate log-intensities based on these profiles. In this
case, the profiles of the four subpopulations are very sim-
ilar because the real sample is best explained by two sub-
populations. Subsequently, we applied our method to the
simulated samples; the results are summarized in Tables 2
and 3.
We learn several things from the simulations (Table 3).
Generally, it is possible to predict the number of subpop-
ulations under the chosen simulation model. However,
samples with 3 or 4 similar subpopulations (Table 3: Real
= 2, Simulated = 3 or 4) are difficult to predict correctly
(48% and 15%, respectively), whereas samples with few
less similar subpopulations are much easier to predict; in
Table 3 simulated samples with 2 subpopulations achieve
a prediction accuracy above 87%.
Next, we estimated the accuracy of the predicted subpop-
ulation percentages and the corresponding profiles (Table
4). When the subpopulation number was predicted cor-
rectly, the estimated subpopulation percentages and copy
number profiles were compared to the values used in the
simulation. Table 4 shows that the copy numbers of the
abnormal subpopulations are predicted correctly for more
than 80% of the clones, with higher accuracy obtained
when there are few subpopulations than many.
Our method of estimation assumes a model of sequential
tumor evolution. To test the method's robustness to viola-
tions of the model we did the following; see Methods
(Simulation)  for details. First we simulated a sample
according to the model. Then, for each segment we mod-
ified the copy numbers by adding/subtracting a Poisson
number of copies. The results are shown in Table 5. Even
when the percentage of segments violating the model is
high, we predict the correct subpopulation number in the
majority of the cases.
Validation experiment
The method was also validated using experimental data.
We performed a series of hybridization experiments with
different combinations of malignant and normal DNA as
follows: 1) The tumor DNA is hybridized with normal
DNA (pooled female healthy population). 2) A combina-
tion of 85% tumor DNA and 15% normal DNA is hybrid-
ized with normal DNA (pooled female healthy
population). 3) A combination of 70% tumor DNA and
Table 2: Primary tumor vs. metastasis
Metastasis
Primary 2 3 4
29 4 2
37 5 1
40 1 0
Shown is the estimated number of subpopulations in the primary 
tumor and the corresponding lymph node metastasis.
Subpopulation development Figure 2
Subpopulation development. Here we show possible 
subpopulation development in two paired tumor samples. 
The dashed lines connect the subpopulations from same 
sample. The solid and dashed lines represent the most likely 
and the least likely development path, respectively. From the 
top-down, the subpopulation contains more and more 
genomic aberrations.BMC Bioinformatics 2009, 10:12 http://www.biomedcentral.com/1471-2105/10/12
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30% normal DNA is hybridized with normal DNA
(pooled female healthy population). The hybridizations
were performed using two different tumor DNA samples.
For each of the hybridizations we estimated the number
of subpopulations and percentages (Table 6). Since we do
not know the composition of the tumor DNA, we do not
know the true number of subpopulations and percent-
ages, but based on our estimates we can predict what the
estimated number of subpopulations and percentages
should be in the mixed samples.
Table 6 shows that the predictions generally are in accord-
ance with our expectations. All discrepancies between
experimental and estimated percentages fall within the
error bounds reported in Table 4. However, one of the
tumor samples is best explained by three subpopulations
(S1 in Table 6), whereas the two mixed samples ("S1 with
15%" and "S1 with 30%") are best explained by two sub-
populations. By adding normal cells the signal from aber-
rant clones become diluted and it becomes more difficult
to distinguish different abnormal subpopulations.
Conclusion
Tumor heterogeneity is an important aspect of tumor evo-
lution and progression. However, this aspect has, to the
best of our knowledge, largely been ignored in analysis of
CGH and SNP array data [12,13]. In Refs. [12,13], a frac-
tion of the tumor is assumed to contain normal cells
which weaken the signal from the aberrated cells. Only
Ref. [13] estimates the fraction of normal cells directly,
but we cannot compare this method to ours since it is
developed to SNP array data. The method described in
Ref. [12] does not output the frequency of normal cells.
We have introduced a novel algorithm to estimate tumor
heterogeneity and evaluated its performance on simulated
and real tumor data. The method adds to our understand-
ing of the genomic aberration profile, the quantification
of genomic instability in the tumor, and the heterogeneity
of the tumor.
One of the main difficulties of developing quantitative
methods for array CGH data is the lack of knowledge
about how tumors evolve and differentiate. Better and
more accurate models could be developed if more were
known about tumor evolution. Therefore, it might be dif-
ficult to make decisions on a strict mathematical basis
only, because the underlying hypotheses might be diffi-
cult test or validate with current data sets. The appropri-
ateness of the novel methodology can only be evaluated
in a long run in which the conclusions demonstrate utility
for improving biological understanding and clinical deci-
sions. Our approach is one possible algorithm to interpret
the biology of the tumor genomic profile.
In CGH array analysis copy number changes are measured
relatively to a reference level. Generally, the reference level
is not known and the median (or mean) log-intensity is
typically assumed to correspond to two copies; loss and
amplifications are then measured relatively to the median
log-intensity level. Our method makes the same assump-
tion. This implies that a tumor sample consisting of e.g.
two subpopulations, one diploid and one n-ploid, would
be identified as purely diploid. Each clone will have a log-
intensity value that reflects the mixture of the two subpop-
ulations and will, erroneously, be equated with two cop-
ies. However, if the two subpopulations are not euploid,
our method might be able to disentangle the two subpop-
ulations. This situation is not unlike traditional CGH
array analysis where the tumor sample will be identified
as one homogeneous population. Only if additional
information is available, e.g. from karyotyping, can the
reference level be properly adjusted.
We anticipate various lines of improvement, both in the
chosen statistical methodology (e.g. to adopt a Bayesian
Table 3: Prediction accuracy for simulated samples
Simulated Predicted as Correct
Real 2 3 4 (in %)
2 2 115 9 0 0.93
36 1 5 9 4 0 . 4 8
4 57 48 19 0.15
3 2 80 11 1 0.87
3 8 78 6 0.85
4 6 60 26 0.28
4 2 15 1 0 0.94
3 0 13 3 0.81
4 0 1 15 0.94
For each real sample four simulated samples were created; in total 
174 samples. The real sample was used as template for the simulated 
samples. In the table, the simulation results are shown according to 
the estimated number of subpopulations in the real samples. Real: 
Estimated number of subpopulations in the real sample, Simulated: 
The number of subpopulations in the simulated sample, Predicted: 
The predicted number of subpopulations in the simulated sample.
Table 4: Accuracy of copy numbers and percentages
#Subpopulations
234
A (in %) 2.05 (2.26) 2.76 (2.50) 4.78 (4.01)
B (in %) 89.5 (13.6) 82.8 (10.0) 80.5 (9.0)
The table shows accuracy of the estimated copy numbers and 
subpopulation percentages when the number of subpopulations is 
correctly predicted. A) The average absolute difference between the 
estimated and true percentages in the simulated samples, B) The 
average number of times the copy number was predicted correctly, 
excluding the normal subpopulation. Standard deviations in 
parenthesis.BMC Bioinformatics 2009, 10:12 http://www.biomedcentral.com/1471-2105/10/12
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framework to control the vast number of copy number
parameters) as well in the mathematical modelling of
tumor progression. These advances should be developed
in tandem with richer and larger data set that are likely to
occur with improved genomic technology. Our method
(and improvements) can also be applied to SNP array
data. Recent methods for SNP array analysis, e.g. [13,14],
distingusih the two possible alleles; this might be useful
for providing more accurate inference on copy numbers
and the copy number level of the reference population,
because each SNP carries two observations and not just
one as for CGH arrays.
Methods
Materials
Cell lines with known copy number gains and losses were
used to establish a copy number model. Here, we applied
several cell lines including trisomy13, trisomy18,
trisomy21 and 49, XXXXX. Normal male and female DNA
were also used.
Twenty-nine pairs of primary breast tumors and their
matched lymph node metastasis were provided by Copen-
hagen University Hospital. The project was approved by
the Scientific and Ethical Committee of the Copenhagen
and Frederiksberg Municipalities.
Arrays covering the whole genome with elements pro-
duced from bacterial artificial chromosome (BAC) clones
were obtained from the Wellcome Trust Sanger Institute.
The human DNA fragments of the 3340 BAC clones are
spaced at approximately 1 Mb intervals across each chro-
mosome arm. The experimental process is explained in
details in [15]. Briefly, each clone is spotted on slides in a
neighboring triplicate pattern. Annotations of the clones
are based on the 1-Mb clone information published by
the Wellcome Trust Sanger Institute and updated using
the 38_36 version of the 1-Mb clone information released
by Ensembl.
Normalization of arrays
The intensities of Cy3 (tumor sample) and Cy5 (refer-
ence) were extracted respectively from 16 bit TIF files
using the Tracker (Applied Precision) software. Subse-
quently data were subjected to quality assessment and a
filtering process to remove the clones with poor quality.
Clones were removed from the subsequent analysis if one
of the following conditions is fulfilled: a) The spot is
labeled "Undetected" by Tracker, b) The Sanger annota-
tion of a clone is inconsistent with the Ensemble annota-
tion (see above), c) The spot's Cy5 (reference) intensity is
less than two times the standard deviation (SD) of its
background intensity, d) Only one spot out of the three
replicates is left after the above procedure, e) The CV of
the intensity ratios Cy3/Cy5 for one clone exceeds 0.08,
and f) The clone maps to chromosome Y.
Table 5: Robustness of the method
3 subpopulations 4 subpopulations
λ 10 . 5 0 . 2 5 10 . 5 0 . 2 5
C o r r e c t 2 72 73 32 72 12 8
Incorrect 19 19 13 13 19 12
A (in %) 4.74 (4.68) 4.15 (3.62) 3.52 (3.70) 7.70 (7.95) 5.43 (4.23) 5.59 (5.03)
B (in %) 5.37 (6.89) 5.59 (6.19) 5.43 (7.13) 7.43 (9.64) 5.65 (5.35) 6.93 (6.98)
Segments (in %) 37.0 24.4 11.5 65.1 45.1 25.6
The table shows results for simulated data not fulfilling the assumption of sequential tumor evolution. With increasing λ, an increasing number of 
samples are incorrectly classified. A) The average absolute difference between the estimated and true percentages in the simulated samples when 
the number of subpopulations are predicted correctly, B) The average absolute difference between the estimated and true percentages of the 
normal subpopulation. Standard deviations in parenthesis. 'Segments' is the number of segments violating the model of sequential tumor evolution.
Table 6: Validation experiment
Estimated based on (X = S1, S2)
Experiment X X with 15% X with 30%
S1 76,24 - 79,21 77,23
S1 with 15% 82,18 80,20 - 81,19
S1 with 30% 84,16 83,17 85,15 -
S1 60,29,11 - 72,20,8 70,21,9
S1 with 15% 76,17,7 66,25,9 - 75,18,7
S1 with 30% 79,15,6 72,20,8 80,14,6 -
S2 62,24,14 - 49,33,18 50,31,19
S2 with 15% 57,28,15 68,20,12 - 57,27,16
S2 with 30% 65,22,13 73,17,10 65,23,12 -
In the "Experiment" column, the estimated subpopulation percentages 
from the 6 experiments are shown: Two pure tumor samples (S1 and 
S2), and four samples with tumor mixed with 15 or 30% normal cells. 
The best fit for S1 is three subpopulations, whereas it is two for "S1 
with 15%" and "S1 with 30%"; therefore we show results for both two 
and three subpopulations to facilitate comparison. The remaining 
three columns contain percentages estimated from the Experiment 
column; e.g. to estimate the percentages of the sample with 85% 
malignant cells and 15% normal cells ("S2 with 15%") from the sample 
S2 do (0.62·85 + 15, 0.24·85, 0.14·85) = (68, 20, 12).BMC Bioinformatics 2009, 10:12 http://www.biomedcentral.com/1471-2105/10/12
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Finally, the ratios of Cy3/Cy5 intensities are calculated
and log transformed. Subsequently, the median of the
log-ratios from the whole array is subtracted from each
log-ratio to normalize all spots.
The copy number model
We modeled the Cy3/Cy5 intensity ratios in the following
way. Assume that the test sample is homogeneous, i.e. a
given clone has the same copy number in all cells in the
sample, and that the clones are divided into distinct seg-
ments such that all clones in a segment have the same
copy number.
Let xij be the ratio of clone j in segment i, and let C0i and
C1i be the copy numbers of the reference sample and the
test sample, respectively. We assume
where γ is a constant depending on the quality of the DNA
in the tube, amplification, scanning and other hybridiza-
tion and experimental conditions. The error term εij is
assumed to have mean zero and common variance, and α
is a constant that is justified from calibration experiments
[see Additional file 1] and appears to be sample independ-
ent (but likely platform specific). The model assumes the
variance is proportional to the true ratio of copy numbers
in the test and reference samples.
Let xR be the median over all intensity ratios (over all seg-
ments). Then
where C1R (C0R) is the copy number of the test (reference)
sample corresponding to xR and ε' is an error term (not
equal to ε). The error term is defined such that (1 + εij)/(1
+ εR) = 1 +  . Typically, the majority of clones in a tumor
sample have copy number two and we assume C1R = 2. In
general, C0i/C0R = 1 in the reference sample, unless the ref-
erence sample has only one chromosome X and C0i/C0R =
1/2 for chromosome X clones.
Put Ci = C1i/C1R, Ci ∈ {0,  , 1,  , ...}, then zij = (1  +
). We refer to zij as the normalized (intensity) ratio.
With this notation we have
Further, assume
log(zij) ~ N(αlog(Ci) + β, σ2), (6)
where β is the mean of   and σ2 the variance. Equation
(3) ensures the variance is independent of the copy
number. If a series of experiments with known copy num-
bers are available, the parameters in equation (6) can be
estimated using linear regression.
In order to determine α and β in equation (6), we used the
normal references and the samples with known copy
number aberrations. We have data corresponding to the
following ratios: 0.5 (46, XY versus 46, XX), 1.5 (47,
XX+13 versus the normal reference, and 47, XX+18 versus
the normal reference), 2 (chr X, the normal females versus
the normal males), and 2.5 (49, XXXXX versus 46, XX).
Mixture modeling of tumor samples
The intensity ratios in a tumor sample is modeled using a
mixture model approach. Specifically, the log-ratio log(zij)
has intensity given by
where
K is the number of subpopulations, pk is the percentage of
the kth subpopulation, Σkpk = 1, and Cik ≥ 0 is the copy
number in the kth subpopulation relative to the copy
number of the test sample. Normally, the same region in
different subpopulations will not experience both gains
and losses [16].
Therefore, we restrict our model parameters in the follow-
ing way. The first subpopulation, with percentage p0, is
assumed to be normal; i.e. Ci0 = 1 for all clones in this sub-
population. We assume the other subpopulations are
derived from each other, such that either
1 = Ci0 ≤ Cik ≤ Ci,k+1 (9)
or
1 = Ci0 ≥ Cik ≥ Ci,k+1.( 1 0 )
x
C i
C i
ij ij =
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⎝
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Classifier Figure 3
Classifier. Here we show three examples of classification of real samples. From top to bottom, the three samples are classi-
fied as 2, 3, and 4 subpopulations, respectively. Each subplot shows two empirical distributions and a blue line representing the 
NLSK of the query sample. In the first column, the black curve is the smoothed empirical distribution (SED) of NLSb22 (simulated 
as two subpopulations and fitted as two) and the red curve is the SED of NLSb32 (simulated as three and fitted as two). In the 
second column, the red curve is the SED of NLSb33 (simulated as three and fitted as three) and the green curve is the SED of 
NLSb43 (simulated as four and fitted as three). Finally, in the last column, the green curve is the SED of NLSb44 (simulated as four 
and fitted as four) and the yellow curve is the SED of NLSb54 (simulated as five and fitted as four). The number in the subplots 
shows how many samples (in %) in the left distribution that obtain a value greater than the value indicated by the blue line.BMC Bioinformatics 2009, 10:12 http://www.biomedcentral.com/1471-2105/10/12
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That is, we consider subpopulation k + 1 to be derived
from subpopulation k by either A) introducing a new copy
number aberration (Cik = 1, but Ci,k+1 ≠ 1), B) increasing an
existing copy number gain, or C) increasing an existing
copy number loss.
Estimation of copy numbers and percentages
To estimate the copy numbers and the percentages of the
subpopulations, we first divide the clones into segments,
such that all clones in a segment have the same copy
number profile. To segment the clones, we used DNAcopy
[17] implemented in R. A comparison study of several seg-
mentation approaches have been done recently [18], and
DNAcopy came out best.
After segmentation, all clones in one segment are assigned
the same value, namely the mean of the intensity values in
that particular segment. Missing clone values mapping
within a segment are given the same value as the segment,
while missing clone values located between segments
have values imputed using the minimum absolute value
of the two flanking segments. The copy number level clos-
est to zero is declared unchanged ("normal level") and
corresponds to two copies. In the final step, all segments
are normalized by subtracting the value of the normal
level.
Denote by   the residual error
where M is the total number of clones, mi the number of
clones in segment i, and
the mean intensity of segment i.
For a given number of subpopulations, K = 2, 3, or 4, we
use least square to fit the parameters (copy numbers, per-
centages); i.e. for each K we minimize
over pk, k = 0, ..., K and Cik with the constraints given in
equations (9) and (10). Here ( ,  ) is obtained from
the samples with known copy number alterations and
assumed to be known in equation (12).
Alternatively, one can minimize
where mi is the number of clones in segment i. Equation
(13) involves summation over fewer terms than equation
(12) and might thus be preferred. For fixed K, there are K
- 1 percentage parameters and K - 1 copy numbers for each
segment; in total (K - 1) + n(K - 1) = (n + 1)(K - 1) param-
eters, where n is the number of segments. The number of
parameters scales with the number of clones; however,
since the copy numbers assume integer values we do not
obtain a perfect fit to the log-intensities in equation (12)
or (13). To facilitate comparison between different exper-
iments, we use the normalized quantity  ,
where n is the number of segments in one experiment.
Classification of samples
To classify a sample we go through the following steps.
The estimation procedure outlined in the previous section
is applied.
Estimation of subpopulation number and parameters
1) Apply DNACopy to obtain a list of segments.
2) Fit K subpopulations to obtain NLSK, K = 2, 3, 4, with
corresponding percentages (p0,  p1, ..., pK) and copy
number profiles (Ci1, ..., CiK). The first subpopulation is
supposed to consist of pure normal cells.
Simulation of bootstrap samples
To simulate bootstrap samples the estimated copy
number profiles are applied. Noise are added to the pro-
files to obtain log-intensity values.
3) Choose α and β according to the estimated normal dis-
tributions obtained by linear regression. The distributions
are restricted to the 95% CI to avoid extreme values.
4) For fixed K, simulate log-intensity values for each esti-
mated copy number profile, k = 1, ..., K, by adding noise:
For a clone with copy number C, compute the mean log-
intensity β + αC and add noise according to a normal dis-
tribution N(0, ).
5) Repeat the previous step B times for each sample and
each value of K to obtain simulated samples with K = 2, 3
or 4 subpopulations. For each simulated sample fit 2, 3
and 4 subpopulations according to step 1 and 2, and cal-
culate the corresponding NLSbKC. Here b denotes the bth
ˆ σ 2
ˆ (log( ) ˆ ) σμ 2 1 2 =− ∑ M
zij j
ij
(11)
ˆ log( ) μi mi
zij
j
= ∑
1
LS z C ij i
ij
=− − () ∑ log( ) log( )
,
αβ
2
(12)
ˆ α ˆ β
LS m C ii i
i
′ =− − () ∑ ˆ ˆ log( ) ˆ , μα β
2
(13)
NLS LS n = ′/
ˆ (log( ) ˆ ) σμ 2 1 2 =− ∑ M
zij j
ijBMC Bioinformatics 2009, 10:12 http://www.biomedcentral.com/1471-2105/10/12
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simulated/bootstrapped sample with K subpopulations,
fitted to C subpopulations, C = 2, 3, 4.
Evaluation of NLSK from real samples
In the final step the NLSK, K = 2, 3, 4, from a real sample
is compared to the bootstrapped samples to find the opti-
mal number of subpopulations for the real sample.
6) If NLS2 is below the 95 percentile of the empirical dis-
tribution of NLSb22, accept the sample as two populations,
otherwise
7) If NLS3 is below the 95 percentile of the empirical dis-
tribution of NLSb33, accept the sample as three popula-
tions, otherwise
8) Accept the sample as 4 subpopulations.
The part described in steps 6–8 is illustrated in Figure 3.
The whole procedure is a bootstrap procedure; for a real
sample the fitted profiles (one for each subpopulation)
are compared to simulated samples with the same profiles
as the fitted. For a (supposedly) normal sample, one can
start with a single population, K = 1 (only normal cells).
Simulation
To test the classifier we choose some of the simulated
samples and used these as input to the bootstrap proce-
dure described above. For each real sample we choose
four simulated samples as input and compared the result
to the known input.
We also tested how robust the classifier is to deviations
from the assumption of sequential tumor evolution. This
we did by adding or subtracting a Poisson number of cop-
ies to the original copy number. For each segment, SiXi
copies were added to the original copy number in subpop-
ulation i. Here, P(Si = 1) = P(Si = 1) = 0.5 and Xi is Pois-
son(λ). If the copy number fell below 0, it was put to zero.
The parameter λ was varied over λ = 0.25, 0.5 and 1. For
each real sample with K = 3 estimated subpopulations we
simulated 2 samples (in total 2·23 = 46 simulated sam-
ples) in this way, and for each real sample with K = 4 we
simulated 4 samples (in total 4·10 = 40 simulated sam-
ples).
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